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Abstract: 
PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a 
central component of the pathway, influencing multiple processes that are 
directly involved in tumourigenesis. Targeting AKT is therefore a highly 
attractive anti-cancer strategy with multiple AKT inhibitors now in various 
stages of clinical development. In this review, we summarise the role and 
regulation of AKT signalling in normal cellular physiology. We highlight the 
mechanisms by which AKT signalling can be hyperactivated in cancers and 
discuss the past, present and future clinical strategies for AKT inhibition in 
oncology. 
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Abbreviations: AE, adverse event; CRPC, castrate resistant prostate cancer; DLT, 
dose limiting toxicity; DNA-PK, DNA-dependent protein kinase; DSB, double 
strand break; GSK3β, glycogen synthase kinase beta; INPP4B, polyphosphate 4-
phosphatase type II; MTD, maximum tolerated dose; OS, overall survival; PD, 
pharmacodynamics; PDK1, 3-phosphoinositide-dependent kinase-1; PFS, 
progression free survival; PH domain, plektrin homology domain; PHLPP, PH 
domain and leucine rich repeat protein phosphatase 1; PI3K, 
phosphatidylinositol 3-kinases; PIP3, phosphatidylinositol-3,4,5-trisphosphate 
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PK, pharmacokinetics; PP2A, protein phosphatase 2A; PR, partial response; 
PTEN, phosphatase and tensin homolog; RP2D, recommended phase II dose; 
RTKs, receptor tyrosine kinases. 
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1. Introduction 
The AGC kinases, named after the protein A, G and C kinases, are an 
evolutionarily conserved group of proteins that share a hydrophobic motif at the 
c-terminus of their catalytic core. This motif, composed of F-X-X-F/Y-S/T-Y/F, is 
known as the PIF-pocket and regulates catalytic activity (Arencibia et al., 2013; 
Manning and Cantley, 2007). The AGC kinase family comprises 14 family 
members, of which AKT (also known as PKB; protein kinase B) is a key member. 
 
There are three AKT isoforms, transcribed from separate genes, which share 
three highly conserved domains: a central catalytic domain and two regulatory 
domains: a lipid-binding N-terminal PH (plektrin homology) domain, and the 
hydrophobic motif (Figure 1). The PH domain contains a lipid-binding module 
that promotes the interaction of AKT with the plasma membrane, an important 
step in AKT activation. The hydrophobic motif contains an important docking 
site for the activating kinase PDK1 (3-phosphoinositide-dependent kinase-1) and 
also provides allosteric regulation of catalytic activity (Scheid & Woodgett, 2003; 
Figure 1).  There is approximately 80% sequence homology between the 
isoforms with most variability occurring in the linker region between the PH and 
catalytic domains (Brodbeck et al., 1999; Cheng et al., 1992; Hanada et al., 2004; 
Jones et al., 1991).  
2. AKT activation 
Mechanisms of AKT activation have been reviewed previously (Liao and Hung, 
2010; Scheid and Woodgett, 2003), but essentially, AKT activity is regulated 
downstream of receptor tyrosine kinases (RTKs), such as those within the EGF 
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(epidermal growth factor), Insulin, PDGF (platelet derived growth factor), FGF 
(fibroblast growth factor) and VEGF (vascular endothelial growth factor) 
families. RTKs activate class I phosphatidylinositol 3-kinases (PI3K), either 
directly, or in conjunction with adaptor proteins such as IRS-1/2 (insulin 
receptor substrate -1/2; Figure 2). The PI3Ks phosphorylate 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-
3,4,5-trisphosphate (PIP3). AKT binding to PIP3 at the plasma membrane 
induces a conformational change that results in phosphorylation of AKT, 
predominantly on two highly conserved residues, Thr308 and Ser473 leading to 
AKT activation (Figure 1). Phosphorylation of Thr308 in the activation T-loop of 
the catalytic domain by PDK1, results in a conformational change that enhances 
substrate affinity and promotes AKT kinase activity (Alessi et al., 1997).  
Phosphorylation of Ser473 within the PIF pocket of AKT by mTORC2 (mammalian 
target of rapamycin complex 2) is thought to promote AKT activity by increasing 
the affinity of AKT to PDK1 (Sarbassov et al., 2005). In fact, multiple different 
kinases for Ser473 have been described in the literature and it’s likely that 
mechanisms determining full activation of AKT are context dependent. It has 
been accepted, for example, that following DNA damage, the PI3K-like kinase 
(PIKK) DNA-PK (DNA-dependent protein kinase) is responsible for AKT Ser473 
phosphorylation and that AKT activation prevents apoptosis following ionizing 
radiation (Bozulic et al., 2008). Multiple other phosphorylation sites on AKT have 
been described, although the physiological importance of these is not yet fully 
understood (Risso et al., 2015) and mechanisms of constitutative activation of 
AKT signalling in cancer are discussed further below. 
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Important negative regulators of the PI3K/AKT signalling pathway include the 
tumour suppressor genes and phosphatases PTEN (phosphatase and tensin 
homolog), PP2A (protein phosphatase 2A) and PHLPP (PH domain and leucine 
rich repeat protein phosphatase 1; Gao et al. 2005), which dephosphorylate PIP3, 
AKT pThr308 and AKT pSer473 respectively (Toker & Marmiroli, 2014; Figure 2). 
PTEN hydrolyses the 3′- phosphate on PIP3 to terminate PI3K signalling. The 
SH2 domain-containing inositol phosphatases (SHIP-1/2) are able to hydrolyse 
the 5′-phosphate on PIP3 to generate PI(3,4)P2, the function of which is not clear, 
although some studies suggest that like PIP3, PI(3,4)P2 is able to facilitate PDK1 
activation of AKT (Gewinner et al., 2009). Recently, a fourth putative tumour 
suppressor of the PI3K/AKT pathway has been described namely, polyphosphate 
4-phosphatase type II (INPP4B; Gewinner et al. 2009). This is able to de-
phosphorylate PI(3,4)P2 to PI(3)P in vitro, resulting in attenuation of AKT 
signalling (Gewinner et al., 2009).  
 
Of all the tumour suppressors, PHLPP in particular is a key regulator of AKT 
activity and it’s ability to fine-tune the PI3K/AKT pathway is discussed in greater 
detail below. 
3. Downstream signalling of AKT 
A consensus phosphorylation motif has been described for AKT substrates: R-X-
R-X-X-S/T-B where X represents any amino acid and B represents bulky 
hydrophobic residues (Alessi et al., 1996). Numerous AKT substrates have been 
published in the literature, with several being extensively validated that impact 
on multiple cellular processes including: cell growth, proliferation and survival, 
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cellular metabolism, glucose uptake and angiogenesis (Table 1; Manning & 
Cantley 2007). Importantly there is great overlap and crosstalk between 
substrate functions, with many substrates being regulated directly by AKT 
phosphorylation, as well as indirectly, through AKT-mediated phosphorylation of 
transcription factors. AKT signalling therefore plays a central role in multiple 
pathways involved in tumourigenesis and hyperactivation of the PI3K/AKT 
pathway is a common occurrence in cancer (Liu et al., 2009).  
4. AKT in normal physiology 
As well as playing a central role in cancer, AKT signalling is also essential for 
normal cellular physiology. In adults, AKT1 expression is ubiquitous, expression 
of AKT2 is elevated in insulin-responsive tissues and expression of AKT3, whilst 
found at low levels in all tissues, is more highly expressed in the brain and 
endocrine tissues (http://www.proteinatlas.org/ ;Uhlen et al. 2010; Uhlén et al. 
2015). 
 
AKT plays an essential role in glucose homeostasis and a deleterious effect of 
pharmacological inhibition of AKT is hyperglycaemia and hyperinsulinaemia 
which correlates with peak plasma level drug concentrations (Crouthamel et al., 
2009). The AKT substrate GSK3β (glycogen synthase kinase beta) 
phosphorylates and inhibits glycogen synthase, preventing glycogen synthesis. 
AKT activation results in phosphorylation and inhibition of GSK3β relieving the 
inhibitory effect on glycogen synthase, resulting in glycogen synthesis. As well as 
stimulating glycogen synthesis, AKT also promotes cellular uptake of glucose by 
prompting translocation of the glucose transporter GLUT4 to the plasma 
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membrane. The AKT substrate directly involved in this process has not been 
well-defined and several candidate proteins are described in the literature 
(Manning and Cantley, 2007).  
 
AKT function (especially AKT1 and AKT2) is also important for regulating 
cardiac growth, contractile function and coronary angiogenesis. It is essential for 
maintaining normal endothelial function and endothelial nitric oxide synthesis, 
with increased atherosclerosis and peripheral vascular disease demonstrated in 
Akt1 knockout mice (Hers et al., 2011). AKT also has a pro-thrombotic effect, 
promoting platelet activation and aggregation, highlighting the need for tight 
control of AKT signalling (Hers et al., 2011). As well as its role in the 
cardiovascular and endocrine systems, AKT has also been shown to be neuro-
protective and plays a role in synaptic transmission between neurons (Hers et al., 
2011). Taken together therefore, given the wide-ranging effects of AKT signalling 
in normal human physiology, there is vast scope for significant on-target as well 
as off-target effects of AKT inhibitors in the clinic. 
5. Selectivity within the AKT pathway  
The phenotypes of Akt null mice have suggested non-redundant roles for the 
three isoforms, with Akt1 knockout being embryonic lethal, Akt2 null mice 
developing insulin-resistant diabetes and Akt3 knock-out resulting in 
microcephaly (Toker and Marmiroli, 2014). In keeping with this, findings from 
pre-clinical studies, are consistent with AKT isoforms having partially 
overlapping, but distinct functions in cancer cells (Clark and Toker, 2014; Toker 
and Marmiroli, 2014). Phosphoproteomic screens have demonstrated unique 
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and common substrates for each of the AKT isoforms and functional studies have 
started to highlight the physiological relevance of these findings, for example 
during RNA processing in lung cancer (Sanidas et al., 2014). Isoform-mediated 
specificity has been best studied in breast cancer models however, where 
differential functions of AKT1, -2 and -3 in both inhibiting and promoting cell 
migration and proliferation have been demonstrated (Clark and Toker, 2014).  
 
AKT1 has been shown to be important for G1-S checkpoint transition and 
proliferation, whereas AKT2 regulates cell-cycle exit through its interaction with 
p21 (Héron-Milhavet et al., 2006). In a recent study in triple negative breast 
cancer, AKT3, rather than AKT1 activity was most important for cellular 
proliferation (Chin et al., 2014a), suggesting a degree of context specificity for 
these findings. Interestingly, it has been observed that although activating 
mutations in AKT1 result in accelerated tumourigenesis, metastatic 
dissemination is decreased due to inhibitory effects of AKT1 on tumour cell 
invasion and migration (Chin and Toker, 2010; Hutchinson et al., 2004). By 
contrast, AKT2 activity promotes tumour invasion and metastatic dissemination 
in mouse breast cancer models (Dillon et al., 2009; Maroulakou et al., 2007). In 
addition, it has recently been shown that INPP4B inhibition of AKT2 is important 
for metastatic spread of follicular thyroid cancer (Chew et al., 2015). A number of 
different AKT1/2 substrates have been described that may account for the 
differential phenotype of cellular migration, which play a role in epithelial-
mesenchymal transition (EMT), including the NFAT transcription factor (Yoeli-
Lerner et al., 2005), palladin (Chin and Toker, 2010), the integrin β subunit 
(Arboleda et al., 2003) and the miR-200 family of micro-RNAs (Iliopoulos et al., 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11
2009). There are likely to be many more (Clark and Toker, 2014) and the relative 
importance of each of these is likely to depend on tumour subtype, as well as 
perhaps tumour stage and genetic background. An example of this is that PTEN 
deficient tumour cells have recently been shown to be dependent, specifically on 
AKT2 for survival (Chin et al., 2014b). This was shown to be true for prostate 
cancer, breast cancer and glioblastoma PTEN deficient cells lines and was at least 
in part, mediated through AKT2 dependent up regulation p21 (Chin et al., 2014b). 
 
Several lines of evidence suggest that AKT does not need to be fully activated in 
order to phosphorylate all substrates. This suggests that different AKT 
substrates and therefore different cellular functions of AKT depend on varying 
levels of AKT activation. For example AKT Ser473 phosphorylation appears to be 
dispensable for phosphorylation of the AKT targets TSC2 and GSK3, as well as 
the TORC1 effectors, S6K and 4E-BP1, but not for FOXO1/3a (Jacinto et al., 2006). 
Interestingly, in patient non-small cell lung cancer samples, AKT Thr308 
correlates with phosphorylation of AKT substrates PRAS40, TSC2 and TBC1D4, 
whereas AKT Ser473 phosphorylation does not (Vincent et al., 2011). This raises 
an important point clinically, when trying to determine whether or not a tumour 
might be dependent on AKT signalling for survival, suggesting the AKT Thr308 is a 
more suitable biomarker of AKT activation than AKT Ser473. 
 
Relative levels of the negative regulators of the PI3K/AKT pathway will also 
ultimately affect amplitude of AKT activation. For example, the PHLPP isoforms -
1 and -2 have been shown to preferentially hydrolyse Thr308 on AKT2 and AKT3 
respectively (Brognard et al., 2007). Cellular location and post-translational 
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modification of AKT isoforms also contribute to specificity within the pathway 
(Clark and Toker, 2014) and untangling all of these factors within the context of 
cancer is proving to be a considerable challenge. 
6. Feedback loops within the PI3K/AKT signalling pathway 
 
The PI3K/AKT signalling pathway is far from linear with multiple negative 
feedback loops fine-tuning overall activation levels (Carracedo and Pandolfi, 
2008). The activity of the S6 kinases (S6K1/2), which are phosphorylation 
targets of mTORC1 play a pivotal role in negatively regulating AKT activity. IRS-1 
(insulin receptor substrate-1) is an adaptor protein required for binding of the 
class IA PI3Ks with insulin and insulin growth factor (IGF) receptors. 
Phosphorylation of IRS-1 by S6K1 inhibits its interaction with insulin and IGF 
receptors and also promotes proteasomal degredation of IRS-1 (Harrington et al., 
2005), thereby dampening PI3K signalling and reducing AKT activity. In addition 
to its effects on AKT activity via upstream inhibition of PI3K signalling, the 
mTORC1 complex also inhibits AKT by up-regulating PHLPP1 translation (Liu et 
al., 2011), the phosphatase responsible for dephosphorylating AKT pSer473 
(Figure 3). 
 
AKT activity is also self-limiting through its substrate GSK3β ; the kinase activity 
of which is negatively regulated by AKT phosphorylation (Figure 3; Li et al. 
2009). GSK3β activation results in phosphorylation and subsequent ubiquitin 
mediated degredation of PHLPP (Li et al., 2009). AKT activation therefore results 
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in GSK3β   and high levels of PHLPP, which in turn, puts the 
brakes on the AKT signalling pathway.  
 
Opposing the above mechanisms that limit the activity of the PI3K/AKT pathway, 
AKT inhibition results in up-regulation of RTKs, in part through loss of mTORC1 
signalling, but also due to FOXO-dependent transcriptional increases in RTK 
expression (Chandarlapaty et al., 2011). This up-regulation of upstream pathway 
components in part will compensate for pharmacological inhibition of more 
downstream players and has been shown to contribute to resistance to AKT 
inhibitors (Garrett et al., 2011b). 
 
In the context of normal growth factor signalling, it’s easy to appreciate why it’s 
advantageous that in ‘times of plenty’, chronic activation of mTORC1, leads to 
attenuation of AKT signalling (Manning, 2004). As discussed below, multiple 
components of the PI3K pathway are mutated or deleted in cancer cells and the 
level of the aberration within the pathway will have profoundly different effects 
on AKT activity depending on whether or not the negative regulatory feedback 
loops are intact. Equally, chronic vs acute inhibition of the pathway may result in 
very different signalling patterns. This makes targeting the pathway a significant 
challenge in oncology and also has implications for dosing schedules of AKT 
inhibitors. 
7. AKT activation in cancer 
The PI3K/AKT pathway is the most commonly disrupted signalling pathway in 
human cancers (Millis et al., 2016). PI3K/AKT pathway aberrations have been 
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identified in up to 40% of all tumour types, with PTEN loss by 
immunohistochemistry occurring most frequently (30%), followed by mutations 
in PIK3CA (13%), PTEN (6%) and AKT (1%; Millis et al. 2016). Whilst activating 
AKT mutations are relatively uncommon, AKT activation can arise as a result of 
several other genomic aberrations. 
AKT amplification 
In keeping with its role in promoting EMT transition and promoting metastatic 
disease, AKT2 is frequently amplified in cancer. Analysis of the cBioPortal 
database for cancer genomics demonstrates that AKT2 amplification is found in 
up to 16% of pancreatic cancers, 16% of uterine cancers, 13% of breast cancers 
and 5-10% of ovarian, lung and bladder cancers (Figure 4A). Early work also 
demonstrated that siRNA depletion of AKT2 resulted in reduced cell growth and 
invasiveness only in cells overexpressing AKT2, consolidating its role in 
tumourigenesis (Cheng et al., 1996). By contrast, AKT1 amplification is found less 
frequently across tumour types, occurring in 20% of neuroendocrine prostate 
cancers, 10% of pancreatic cancers and 3-5% of breast and serous ovarian 
cancers. To date, high levels of AKT3 amplification have been identified most 
often in breast cancers and as discussed, AKT3 may be the predominant isoform 
responsible for growth and proliferation of triple negative breast cancers (Chin 
et al., 2014a). Interestingly, high levels of AKT3 expression have also been 
demonstrated in over 25% of neuroendocrine prostate cancers (Figure 4A). 
AKT mutations 
In contrast to amplifications, mutations in AKT2 are found much less frequently 
and to our knowledge, no commonly occurring functionally activating mutations 
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in AKT2 have been described. AKT1 is the most frequently mutated isoform in 
tumours and this occurs at low frequency (approximately 1% of all cancers; 
Figure 4B; www.cbioportal.org; Cerami et al. 2012; Gao et al. 2013). Several 
functionally transforming mutations of AKT1 have been described however (Yi et 
al., 2013), the predominant mutation is AKT1E17K (Carpten et al., 2007). This 
glutamic acid to lysine substitution within the lipid-binding pocket of AKT1 
results in pathological localisation of AKT1E17K to the plasma membrane and 
subsequent constitutative activation of AKT1 signalling (Carpten et al., 2007). In 
contrast to physiological AKT1 activation that occurs upon binding of AKT1 to 
PIP3 at the plasma membrane, the E17K mutation in AKT1 alters PIP specificity, 
resulting in high affinity binding to highly abundant PIP2 within the plasma 
membrane (Landgraf et al., 2008). AKT1E17K therefore utilises both PIP3 as well 
as PIP2 for its activation and as a result, remains constitutively active at the cell 
membrane (Landgraf et al., 2008).  
 
Both allosteric and catalytic inhibitors of AKT are capable of suppressing 
AKT1E17K activity and subsequently inhibiting growth of tumours harbouring 
AKT1E17K in breast cancer models (Davies et al., 2015). AKT1E17K mutations are 
found most frequently in breast, bladder, cervix and prostate cancers (Figure 
4B). Inhibition of AKT1E17K tumours in a clinical setting has also now been 
demonstrated and will be discussed in more detail below. 
Alterations of other proteins of the PI3K/AKT signalling pathway 
Over-expression or activating mutations of proteins upstream of AKT in the 
PI3K/AKT pathway result in AKT activation, as do loss of the tumour suppressor 
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proteins: PTEN, PHLPP, PP2A and INPP4B (Liu et al., 2009). Germline mutations 
in PTEN result in PTEN hamartoma syndromes, of which Cowden’s syndrome is 
the best described; characterised by the development of multiple hamartomas 
and with increased risk of carcinomas of the breast, thyroid, endometrium and 
kidney. Somatic PTEN loss is most commonly identified in endometrial 
carcinoma, prostate carcinoma and glioblastoma and can arise due to mutations, 
insertions and deletions throughout the PTEN gene (Hollander et al., 2011). 
8. The clinical development of AKT inhibitors 
Inhibiting PI3K/AKT signalling has long been an attractive therapeutic approach 
in oncology. Numerous compounds that inhibit the pathway at all levels are now 
in clinical development, including those targeting AKT (Yap et al., 2008).  AKT 
inhibitors fall predominantly into two separate classes. Allosteric inhibitors of 
the AKT PH-domain prevent localisation of AKT to the plasma membrane, 
thereby blocking AKT phosphorylation and activation. The second class of 
inhibitors comprise ATP- competitive inhibitors of AKT, of which there are 
several in the early stages of clinical development (Table 2). 
Monotherapy with AKT inhibitors 
The AKT inhibitors that have entered clinical evaluation have been discussed in 
alphabetical order. 
AFURESERTIB (GSK2110183) AND GSK2141795 
Afuresertib (GSK2110183) and GSK2141795 (GlaxoSmithKline) are both orally 
bioavailable, ATP-competitive inhibitors of AKT1-3 which have anti-tumour 
effects in vitro and in vivo as monotherapy and in combination with the MEK 
inhibitor trametinib (GSK1120212; Dumble et al. 2014). In a phase I trial of 
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afuresertib in patients with haematological malignancies, DLTs consisted of 
deranged liver function tests and the MTD was established as 125mg daily. The 
most frequent (>10% of patients) treatment-related adverse events (AEs) were 
nausea (23.3%), diarrhoea (20.5%), dyspepsia (19.2%), fatigue (16.4%), 
gastrointestinal reflux disease (15.1%), and anorexia (13.7%). Promising anti-
tumour activity was demonstrated in patients with multiple myeloma (Spencer 
et al., 2014). Preliminary data from a phase I study of GSK2141795 
demonstrated an MTD of 75mg daily with DLTs of G3 hyperglycaemia, G4 
hypoglycaemia, G3 hypoglycaemia and G2 stomatitis with promising tumour 
responses seen in patients with an activated PI3K/AKT pathway (Burris et al., 
2011).  
ARQ 092 and ARQ 751 
ARQ 092 and ARQ 751 (ArQule) are both highly potent allosteric inhibitors of 
wild type and AKTE17K, with ARQ 751 having enhanced PK properties and 
potency (Table 2; Lapierre et al., 2016; Yu et al., 2015). Structural studies have 
shown that allosteric inhibitors bind to a region between the PH-domain and 
kinase domain on AKT (Wu et al., 2010). This stabilises the PH-domain in a 
‘closed’ conformation which blocks ATP binding to the kinase site, obstructing 
the phospholipid binding site, and thereby inhibiting AKT recruitment to the 
plasma membrane (Wu et al., 2010).  
 
Preliminary data from a phase Ia dose escalation trial of ARQ 092 has 
demonstrated common drug-related adverse events (≥10%) of hyperglycaemia 
(30%), macular-papular rash (28%), nausea (20%), diarrhoea (19%), pruritis 
(16%), fatigue (15%_ and decreased appetite (14%; Tolcher et al., 2016). Early 
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evidence of anti-tumour activity has been shown with two durable partial 
responses in patients with activating PIK3CA mutations (Tolcher et al., 2016) and 
promising clinical activity in patients with AKTE17K mutations has also now been 
demonstrated in the phase Ib expansion cohort (Abbadessa et al., 2015).  
 
Interestingly, AKT inhibition using ARQ 092 is also being explored for the 
treatment of Proteus syndrome (Lindhurst et al., 2015). Rarely a somatic 
AKT1E17K mutation can arise during development that results in Proteus 
syndrome; a progressive, mosaic, segmental overgrowth syndrome that can 
affect any part of the body (Biesecker, 2001). The severity and extent of tissue 
involvement is unique to each patient, with bone, fat, skin and connective tissue 
being most commonly involved (Biesecker, 2001). Affected patients have an 
increased risk of malignancy, including mesothelioma and breast cancer, and are 
at high risk of life-threatening venous thromboembolism (Biesecker, 2001). In 
preclinical studies, ARQ 092 has been shown to suppress AKT signalling in cell 
lines and tissues from patients with Proteus syndrome (Lindhurst et al., 2015). 
In contrast to the treatment of AKT-mutated cancers, the aim of such treatments 
is to restore physiological levels of AKT signalling in cells rather cytotoxicity. A 
phase I trial of ARQ 092 is currently recruiting children and adults with Proteus 
syndrome (NCT02594215) and preliminary data suggest that doses of ARQ 092 
that are significantly lower than the MTD for cancer will be sufficient to treat 
patients with Proteus syndrome (Lindhurst et al., 2015). 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 19
AZD5363 
AZD5363 (Astrazeneca) is a potent competitive kinase domain inhibitor of 
AKT1-3, which in pre-clinical studies has been shown to inhibit phosphorylation 
of AKT substrates (PRAS40, GSK3β and S6) and tumour growth in xenograft 
models (Davies et al., 2012). The presence of an activating PIK3CA mutation, 
AKT1E17K mutation or PTEN loss, in the absence of a significant KRAS (or other 
activating mutation in an alternative pro-survival pathway) significantly 
correlated with sensitivity to AZD5363 across a range of tumour cell lines 
(Davies et al., 2012, 2015). Interestingly, continuous low doses of AZD5363 had a 
predominantly anti-proliferative effect on cells when given as monotherapy and 
significant levels of apoptosis were only observed using an intermittent high 
dose schedule, suggesting that intermittent high dose schedules might be a more 
effective clinical strategy for the treatment of AKT dependent tumours (Davies et 
al., 2012).  
 
A phase I trial of AZD5363 monotherapy in patients with solid tumours has 
investigated the toxicity, pharmacokinetics (PK) and PD of intermittent vs 
continuous dosing (Banerji et al., 2015). Three schedules were explored: 
continuous dosing (7/7), four days a week (4/7) and two days a week (2/7) of 
which the MTDs were 320mg BID, 480mg BID and 640mg BID respectively. The 
DLTs were rash and diarrhoea for 7/7, and hyperglycaemia for 2/7 with no DLTs 
identified for 4/7. As expected following AKT inhibition, the most common 
causally related adverse events ≥ CTC Grade 3 were hyperglycaemia (20%), 
diarrhoea (10%), rash (10%), nausea (3%) and fatigue (1%). PK profiles at 
480mg BID (4/7) resulted in higher steady state levels of AZD5363 compared to 
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continuous dosing at lower drug concentrations and were consistent with 
exposures that resulted in tumour regression in preclinical models. Pre- and 
post-treatment biopsies confirmed target engagement in tumour tissue, with an 
increase in pAKT and reductions in pGSK3β and pPRAS40. Based on PK, PD and 
toxicity data, 480mg BID (4/7) was determined as the RP2D of AZD5363. Early 
data from an expansion cohort at this dose in patients with breast or 
gynaecological tumours harbouring PIK3CA mutations demonstrated anti-
tumour activity in approximately 50% of patients with PIK3CA mutations 
although the magnitude of response in most patients was not deemed sufficient 
to go forward with monotherapy in a PIK3CA mutant population. Preliminary 
expansion data at the RP2D in patients with AKT1 E17K mutations (without 
concomitant RAS/RAF mutations) has shown very promising anti-tumour 
activity. At the time of reporting, 13/17 (76%) ER+ve breast,  8/10 (80%) 
gynaecological and 10/12 (83%) other solid tumour patients demonstrated 
target lesion responses with 4 (24%), 2 (20%) and 3 (25%) partial responses 
(PRs) respectively (Hyman et al., 2015). A phase I trial of AZD5363 monotherapy 
in Japanese patients with solid tumours has also determined 480mg BID (4/7) to 
be the RP2D and demonstrated 2 PRs in patients with AKT1E17K mutations 
(Tamura et al., 2016). AKT1E17K is therefore a promising predictive biomarker for 
response to AZD5363 monotherapy across a range of tumour types and the full 
results of this trial are awaited with interest. 
IPATASERTIB (GDC-0068) 
Optimisation of ATP-competitive AKT inhibitors using structure based design led 
to the discovery of ipatasertib (GDC-0068; Genentech), a potent and highly 
selective inhibitor of AKT1-3 that causes dose-dependent AKT signalling 
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inhibition in cancer cells and xenograft tumour models (Blake et al., 2012; Lin et 
al., 2013). In pre-clinical models, markers of hyperactive AKT signalling 
correlated with sensitivity to ipatasertib, including high basal phospho-AKT 
levels, PTEN loss and PIK3CA mutations (Lin et al., 2013). Preliminary data from 
a phase I study established the MTD as 600mg QD of ipatasertib, with two DLTs 
of fatigue at higher dose levels and a low incidence of clinically significant 
hyperglycaemia (Yan et al., 2011). A dose- and time-dependent PD response was 
demonstrated through inhibition of pGSKβ in platelet rich plasma in doses above 
200mg (Yan et al., 2011, 2013). As with AZD5363, the clinical focus for 
ipatasertib is now on combination studies (see below). 
MK-2206 
MK-2206 (Merck; MSD) is the most clinically advanced allosteric inhibitor of 
AKT, although other allosteric inhibitors of AKT include ARQ092 (ArQule; 
Lapierre et al., 2016), ARQ751 (ArQule; Yu et al., 2015) and BAY1125976 (Bayer; 
Politz et al., 2016; Table 2).  
 
MK-2206 is a predominantly AKT1/2 inhibitor with reduced potency against 
AKT3 (Yan, 2009) and has been shown to have single agent activity against a 
range of cell lines harbouring RTK activation, PTEN loss/mutation and/or AKT2 
amplification (Lu et al., 2009). A phase I trial of MK-2206 monotherapy in 
patients with solid tumours demonstrated a MTD of 60mg on alternate days with 
DLTs of skin rash and stomatitis (Yap et al., 2011). Drug related AEs included 
rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycaemia (21.2%), and 
diarrhoea (21.2%). MK-2206 had a long half life of 40-100 hrs and plasma 
concentrations declined in a biphasic manner (Yap et al., 2011). On-target PD 
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tumour effects were also demonstrated (decrease in AKT pSer473). Similarly to 
other AKT inhibitors, intermittent dosing schedules seem to be better tolerated 
and equally, if not more effective. Compared to the alternate day schedule, once 
weekly dosing of MK-2206 was equally as well tolerated up to a recommended 
phase II dose (RP2D) of 200mg with pulsatile inhibition of AKT demonstrated in 
tumour biopsies (Yap et al., 2014). Given the limited anti-tumour activity seen 
with MK-2206 monotherapy in phase II trials across a range of tumour types, 
attention has focused on combination trials (Table 2 and see below). 
PERIFOSINE 
The first AKT inhibitor to enter clinical development was in fact an 
alkylphospholipid, perifosine (D-21266; KRX0401; Aeterna Zentaris). 
Alkylphospholipids accumulate in the plasma membrane and inhibit AKT 
activation by disrupting the interaction between AKT and the phospholipids 
(Kondapaka et al., 2003). As such, these compounds are relatively non-selective 
(Hideshima et al., 2006). In clinical studies, doses of oral perifosine are limited 
by gastro-intestinal (GI) toxicity when administered daily and several studies 
have tested different loading and maintenance schedules in order to achieve 
administration of biologically active doses without intolerable toxicity (Crul et al., 
2002; Figg et al., 2014; Van Ummersen et al., 2004; Unger et al., 2010). Multiple 
Phase II trials have been conducted using a loading dose/maintenance dose 
schedule (Table 2) and of those reported, perifosine monotherapy has shown 
modest anti-tumour activity in soft tissue sarcomas and renal cell carcinomas 
(Bailey et al., 2006; Cho et al., 2012; Knowling et al., 2006).  
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Combination strategies with AKT inhibitors 
Activation of the PI3K/AKT pathway has been implicated in resistance to a 
number of anti-cancer agents, providing a strong rationale for the clinical 
exploration of AKT inhibitor combinations.  
CHEMOTHERAPY 
AKT activation has been linked to both chemotherapy and radiation resistance. 
DNA-PK is one of the apical kinases involved in DNA double strand break (DSB) 
repair and is essential for classical non-homologous end-joining, the 
predominant repair pathway of DSBs in human cells (Jette and Lees-Miller, 
2015). Following the generation of DNA DSBs, AKT is activated in a DNA-PK –
dependent manner and promotes survival through anti-apoptotic mechanisms 
that are not well described (Bozulic et al., 2008; Brown et al., 2015; Wendel et al., 
2004). In pre-clinical studies, AKT inhibition has been shown to hypersensitise 
cells to a number of chemotherapeutic agents (Davies et al., 2012; Hirai et al., 
2010; VanderWeele et al., 2004).  
 
Continuous low dose perifosine has been combined safely with a number of 
chemotherapies (Table 2). A randomised phase II trial of capecitabine +/- 
perifosine as second or third line treatment for metastatic colorectal cancer 
showed a significant OS benefit of the combination (17.7 v 7.6 months; P = .0052; 
Bendell et al. 2011), however these results were not validated in the phase III 
setting (Bendell et al., 2012). Interestingly, the presence of a PIK3CA mutation or 
PTEN loss did not predict for response to the capecitabine/perifosine 
combination which may in part be due to the high levels of KRAS mutations in 
colorectal cancers (Eng et al., 2014).  
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AZD5363 significantly enhances the activity of docetaxel in xenograft studies 
(Davies et al., 2012). Preliminary data from a phase I trial of AZD5363 in 
combination with docetaxel in patients with metastatic castrate resistant 
prostate cancer (mCRPC) has determined a RP2D of 320 mg BID 4 days on/3 
days off in combination with full dose docetaxel (75mg/m2 q3w) and 
prednisolone (5mg BID D1-21; Crabb et al. 2016). DLTs were G3 rash and G3 
diarrhoea. The randomised phase II trial is currently recruiting (ProCAID, 
NCT02121639). Early results from a phase Ib study determined a RP2D of 
400mg ipatasertib QD days 1-21 q4w in combination with weekly paclitaxel 
90mg/m2 with grade 3 AEs of diarrhoea, fatigue and hyperglycaemia at higher 
doses (Bendell et al., 2014). Promising anti-tumour activity was demonstrated in 
breast cancer patients with 6 PRs (22%) including 4 patients who had previously 
progressed on paclitaxel (Bendell et al., 2014). Similarly, phase I/II trials of 
AZD5363 in combination with weekly paclitaxel are on going in breast and 
gastric cancer populations with results awaited (Table 2). 
 
Activation of AKT has been associated with platinum resistance in pre-clinical 
studies of ovarian cancer (Stronach et al., 2011). In a phase I/II study of 
afuresertib in combination with carboplatin (iv AUC5 q3w) and paclitaxel (iv 
175mg/m2 q3w), the MTD of afuresertib was 150mg daily with DLTs of G3 rash, 
G2 febrile neutropenia and G2 lip swelling (Blagden et al., 2016). Promising anti-
tumour activity of the combination was demonstrated and at the time of 
reporting, overall response rate (ORR) for platinum-resistant patients was 
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32.1% (95% CI: 15.9–52.4) and median progression free survival (PFS) was 7.1 
months (95% CI: 6.3–9.0).  
PARP INHIBITORS 
Pre-clinical studies have demonstrated synergy between PI3K inhibition and 
PARP inhibition in BRCA1/2 mutant mouse models (Juvekar et al., 2012). The 
mechanism of this synergy has not yet been fully explained. Published data 
suggests that PI3K inhibition impairs DSB repair by homologous recombination 
through reduced expression of BRCA1 and BRCA2 (Ibrahim et al., 2012). It is also 
likely however, that as with chemotherapy, the anti-apoptotic/pro-survival 
effects of PI3K inhibition are important in this setting. Preliminary data have 
shown promising anti-tumour activity of AZD5363 in combination with olaparib 
across a range of tumour types (Michalarea et al., 2016). At the time of reporting, 
out of 37 evaluable patients, there were 10 RECIST partial or complete responses, 
including 3 patients with BRCA wild-type tumours and 1 patient who had 
previously been treated with a PARP inhibitor. The recommended phase II 
schedules of this combination are 300mg BID olaparib + 400mg BID 4/7 
AZD5363 or 300mg BID olaparib + 640mg BID 2/7 AZD5363. Common G1-2 
toxicities were nausea, fatigue, anaemia, diarrhoea, anorexia, mucositis and 
vomiting on both schedules. 
RTK/PI3K/AKT/MTOR INHIBITORS 
Given the multiple feedback loops within the PI3K-AKT signalling pathway, dual 
inhibition at different levels seems like a sensible strategy, although over-lapping 
toxicities limits dosing.  
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Pre-clinical studies have demonstrated synergy between EGFR and AKT 
inhibition in EGFR-wild type and mutant NSCLC cell lines (Puglisi et al., 2014) 
and a number of early phase studies of gefitinib or erlotinib in combination with 
MK-2206 have been completed (Table 2). The most common grade 3 AEs in a 
phase II trial of erlotinib 150mg orally OD with MK-2206 200mg weekly, in 
patients with erlotinib-resistant NSCLC, were rash, diarrhoea, fatigue and 
mucositis (Lara et al., 2015). Although partial response rates were low in both 
EGFR wild-type and -mutant tumours (9% and 3% respectively) a disease 
control rate of 43% in EGFR-wild type tumours met pre-specified levels of 
clinical activity to warrant further investigation. A phase I trial has also shown 
tolerability of gefitinib in combination with MK-2206 with a RP2D of 250mg 
gefitinib daily and 200mg MK-2206 weekly with early signs of clinical activity in 
EGFR resistant patients with NSCLC (Lin et al., 2014). A phase II trial exploring 
erlotinib in combination with MK-2206 as part of the BATTLE-2 program 
(NCT01248247) is on going.  
 
PTEN loss and activating PIK3CA mutations have been associated with relative 
resistance to trastuzumab both in clinical and pre-clinical studies (Berns et al., 
2007; Junttila et al., 2009; Nagata et al., 2004). Inhibition of HER2/ErbB2 with 
trastuzumab has been shown to activate PTEN and attenuate PI3K/AKT 
signalling (Junttila et al., 2009; Nagata et al., 2004). Trastuzumab-induced 
growth inhibition has also been shown to correlate with inhibition of AKT 
signalling in HER2 +ve cells and combined inhibition of HER2 and AKT signalling 
is synergistic (Junttila et al., 2009). MK-2206 has in particular, been shown to be 
well-tolerated in combination with trastuzumab and paclitaxel/trastuzumab in 
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phase I trials, demonstrating promising anti-tumour activity in HER2+ and 
paclitaxel refractory tumours (Chien et al., 2016; Hudis et al., 2013). 
 
Results of a phase I trial of the mTOR inhibitor ridaforolimus in combination 
with MK-2206 demonstrated an MTD of 10mg ridaforolimus OD for 5/7 and 
90mg MK-2206 weekly with 1/17 patients experiencing a DLT (G3 rash) at this 
dose (Gupta et al., 2015). Other common AEs included skin rash, stomatitis, 
diarrhoea and anorexia. Promising anti-tumour activity was demonstrated in a 
number of heavily pre-treated breast cancer patients in an expansion cohort 
comprising patients with a low ‘RAS pathway signature score’, a 147-gene 
signature that has been shown to correlate with tumour dependence on RAS 
signalling and resistance to PI3K pathway inhibition (Loboda et al., 2010).  
MAPK PATHWAY INHIBITORS 
There are now several lines of evidence showing that tumours harbouring 
activating mutations in both the PI3K/AKT and MAPK signalling networks, 
require inhibition of both to negatively affect tumour growth and survival, due to 
significant crosstalk and redundancy between the pathways (Davies et al., 2012; 
She et al., 2010). Doses of MK-2206 in combination with the MEK inhibitor 
selumetinib in a phase I trial of patients with solid tumours were limited 
predominantly by skin rash, diarrhoea and stomatitis (Tolcher et al., 2015a). The 
RP2D was defined as MK-2206 135mg weekly and selumetinib 100mg daily, with 
dose reductions of both drugs required due to overlapping toxicity. Significant 
tumour responses were seen in patients with KRAS-mutant NSCLC and low-
grade ovarian cancer, but not in KRAS-mutant colorectal cancer, again suggesting 
differences in biology based on tumour context. Preliminary data from a phase II 
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trial of MK-2206 in combination with selumetinib in patients with pre-treated 
KRAS mutant NSCLC has shown a disease control rate of 61% 
(Papadimitrakopoulou et al., 2014) and the full results of this study are awaited 
with interest. 
 
Preliminary results from a phase Ib study of ipatasertib in combination with the 
MEK inhibitor cobimetinib has shown early evidence of anti-tumour activity, but 
tolerability has been challenging (Bendell et al., 2014). Afuresertib has also been 
tested in combination with a MEK inhibitor, trametinib with only intermittent 
dosing being tolerable (Tolcher et al., 2015b). Continuous dosing schedules of 
GSK214795 in combination with trametinib have been achieved (Algazi et al., 
2015; Shoushtari et al., 2016) and a number of trials exploring GSK2141795 in 
combination with trametinib are ongoing (Table 2). Preclinical data has clearly 
demonstrated that sub-maximal inhibition of the combination of MEK and AKT 
does not significantly increase growth inhibition of BRAF or PIK3CA mutant cells, 
compared to maximally inhibiting MEK or AKT alone (Stewart et al., 2015). This 
has significant implications for the clinical development of such combinations 
and requires intelligent phase I trial design that tests optimal schedules as well 
as doses (Lopez and Banerji, 2016). 
HORMONAL TREATMENTS 
The development of castrate resistant prostate cancer (CRPC) is associated with 
reactivation of the androgen receptor axis as well as up-regulation of other pro-
survival pathways including the PI3K pathway (Morgan et al., 2009). The 
PI3K/AKT pathway is activated in 30-50% of prostate cancers, most commonly 
through loss of PTEN, however inhibition of this pathway alone results in up-
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regulation of AR signalling leading to resistance (Carver et al., 2011). In pre-
clinical studies, synergistic inhibition of AKT and androgen receptor signalling 
using either bicalutamide or enzalutamide results in sustained tumour growth 
inhibition and PSA stabilisation in mouse models of CRPC (Thomas et al., 2013; 
Toren et al., 2015). Preliminary data from a phase I/II study of ipatasertib in 
combination with abiraterone, has shown promising clinical benefit in patients 
with CRPC (De Bono et al., 2016). Patients with mCRPC, previously treated with 
docetaxel, were randomized 1:1:1 to three arms: ipatasertib 400mg, ipatasertib 
200mg, or placebo, all in combination with abiraterone 1000 mg and prednisone 
10 mg daily. Compared to placebo, ipatasertib 400mg showed increased 
radiological PFS (median 8.2 vs 6.4 m; HR = 0.75; p= 0.17) and increased OS for 
ipatasertib 400mg vs placebo (median 18.9m vs 15.6m; HR = 0.72; p= 0.22) (De 
Bono et al., 2016). Patients with PTEN loss had a superior PFS benefit (De Bono 
et al., 2016). Full results of this trial are awaited with interest. A randomised 
phase II trial of enzalutamide +/- AZD5363 in patients with mCRPC (RE-AKT, 
NCT02525068) is currently recruiting. Similarly, in ER +ve breast cancer, 
hormone resistance is also associated with an increased dependence on 
PI3K/AKT signalling (Miller et al., 2010) and treatment of breast cancer cell lines 
and xenografts with AZD5363 in combination with fulvestrant is superior to 
AZD5363 alone (Fox et al., 2013; Ribas et al., 2015). FAKTION (NCT01992952), a 
randomised phase II trial of fulvestrant +/- AZD5363 is ongoing. 
9. Future directions and conclusions 
AKT remains a central player in the PI3K-AKT signalling network and promising 
data from a number of phase II combination trials look set to pave the way for 
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phase III studies and hopefully, clinical registration of some these compounds. 
Patient selection remains key, with AKT1E17K looking like a particularly strong 
biomarker predictive of response to AZD5363 monotherapy. A basket trial 
approach to clinical trial design is becoming increasingly popular and suits 
collections of low frequency, but high potency mutations such as AKT1E17K. 
Although potentially slow to complete, the clinical impact for patients 
harbouring such mutations should not deter licensing of compounds for such 
niche tumour populations. 
 
The presence of AKT1E17K and other genetic aberrations (such as activating 
PIK3CA mutations and PTEN loss) needs to be put in molecular context however 
as co-activation of other pro-survival pathways is likely to require combination 
treatment strategies as demonstrated with AKT and MEK inhibition. Other 
potential biomarkers such as the RAS pathway signature score and proteomic 
signatures predictive of response to AKT inhibitors attempt to look beyond the 
PI3K/AKT pathway itself and should be explored further (Cheraghchi-Bashi et al., 
2015; Loboda et al., 2010).  
 
Interestingly, intermittent high doses of AKT inhibitors have been shown to be a 
more effective strategy both clinically and pre-clinically. High doses appear to be 
required for induction of apoptosis and intermittent schedules overcome the low 
therapeutic index of these compounds. This is particularly important in 
combination studies where toxicity is often limiting (Shimizu et al., 2012). 
Current preclinical data suggests intermittent dosing that inhibits AKT signalling 
to a greater extent is more efficacious than chronically inhibiting AKT to a lesser 
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degree as a clinical strategy (Lopez and Banerji, 2016; Stewart et al., 2015). 
Interestingly due to feedback inhibition within the PI3K/AKT pathway, 
intermittent dosing may also delay treatment resistance. Despite the challenges, 
there remains intense enthusiasm in establishing AKT inhibitors within the 
future collection of personalised treatments for cancer and numerous clinical 
trials of AKT inhibitor combinations are actively recruiting. 
 
The potential applications of AKT inhibitors are numerous. The scientific 
community has multiple drugs in the clinic with exciting potential to influence 
treatment paradigms in multiple cancers. Carefully thought out clinical trials 
with tolerable clinical schedules, appropriate combinations and patient selection 
biomarkers will be needed to maximally exploit the full potential of this class of 
agents. 
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Cellular function Substrate Effect of AKT phosphorylation 
Cell survival BAD Release of pro-survival Bcl-2 proteins from BAD.  
FOXO1 
FOXO3a 
FOXO4 
14-4-4 mediated export of FOXO transcription factors from the nucleus, 
blocking transcription of pro-apoptotic proteins such as BIM and FasL. 
MDM2 Nuclear translocation of MDM2 resulting in P53 ubiquitin-mediated 
degredation. 
Cell growth TSC2 Inhibits TSC2 function, resulting in mTORC1 activation. 
PRAS40 Phosphorylation of PRAS40 by AKT results in 14-3-3 mediated sequestration 
of PRAS40 and mTORC1 activation. 
Cell proliferation CDKN1B/p27 
CDKN1A/p21 
Prevents nuclear localisation of cyclin dependent kinases, blocking cell-cycle 
inhibitory effects and resulting in loss of the G1-S checkpoint.  
Glucose 
homeostasis 
Unknown Results in translocation of glucose transporter 4 (GLUT4) to the plasma 
membrane. 
GSK3β Inhibits glycogen synthase 3 (GSK3), thereby inhibiting glycogen synthesis. 
Angiogenesis eNOS Activates endothelial nitric oxide synthase (eNOS), resulting in 
vasodilatation, vascular remodelling and angiogenesis. 
 
Table 1: The effect of AKT phosphorylation on well-described substrates 
(Manning and Cantley, 2007). BAD (BCL2 Associated Agonist Of Cell Death); 
FOXO (Forkhead Box); MDM2 (MDM2 oncogene); TSC2 (Tuberous Sclerosis 2); 
PRAS40 (Proline Rich Akt substrate); CDKN (Cyclin-Dependent Kinase 
Inhibitor); GSK3β (Glycogen Synthase Kinase Beta). 
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AFURESERTIB (GSK2110183) 
Monotherapy 
Phase I: 
 
Phase I/II:  
Multiple myeloma (NCT02177682); Haematological malignancies (NCT00881946) (Spencer et al., 
2014); Healthy volunteers (NCT01827644, NCT02040480) 
Solid tumours (NCT01531894) (Yan et al., 2011) 
Chemotherapy 
Carboplatin + Paclitaxel 
Paclitaxel 
Platinum resistant ovarian cancer (NCT01653912) (Blagden et al., 2016) 
Gastric cancer (NCT02240212) 
MAPK Trametinib Solid tumours (NCT01476137) (Tolcher et al., 2015b) 
Other 
Bortezomib + Dex 
Ofatumumab 
Multiple myeloma (NCT01428492) 
CLL (NCT01532700) 
ARQ 751 and ARQ 092 
Monotherapy Phase I: Solid tumours (NCT01473095); Solid tumours with PIK3CA or AKT1/2/3 activating mutations 
(NCT02761694,); Proteus syndrome (non-oncological indication; NCT02594215) 
Combinations Carboplatin +/- paclitaxel 
or anastrazole 
Ovarian, endometrial, cervical and TNBC (NCT02476955) 
AZD5363 
Monotherapy 
Phase I: Solid tumours (NCT01226316, NCT01353781, NCT01895946) (Banerji et al., 2015; Dean et al., 2015; Tamura et al., 2016); 
mCRPC (NCT01692262). Expansion cohorts in PIK3CA and AKT mutant breast and gynaecological cancers. 
Phase II: Solid tumours with molecular match (NCT02465060); ER+ve breast cancer vs placebo (NCT02077569); NSCLC 
(NCT02664935, NCT02117167); Lymphoma (NCT02465060); metastatic breast cancer (NCT02299999) 
Chemotherapy/ 
Radiotherapy 
Paclitaxel 
 
Docetaxel + Prednisolone 
TNBC (NCT02423603); ER+ breast cancer (NCT01625286); Gastric cancer (NCT02449655, 
NCT02451956) 
CRPC (NCT02121639) (Crabb et al., 2016) 
Targeted 
therapy/ 
hormonal therapy 
Olaparib 
Olaparib + AZD2014 
Enzalutamide 
Fulvestrant 
Solid tumours (NCT02338622; NCT02576444) (Michalarea et al., 2016) 
Endometrial and ovarian cancers (NCT02208375)  
CRPC (NCT02525068) 
ER+ breast cancer (NCT01992952) 
BAY1125976 
Monotherapy Phase I: Solid tumours (NCT01915576) 
GSK2141795 
Monotherapy Phase I: Solid tumours (NCT00920257); Ovarian cancer (NCT01266954) 
MAPK 
Trametinib 
 
 
 
Trametinib/Dabrafenib 
Solid tumours (NCT01138085, NCT01138085); AML (NCT01907815); Multiple Myeloma 
(NCT01989598); Endometrial cancer (NCT01935973, NCT02093546); TNBC (NCT01964924); Uveal 
melanoma (NCT01979523) (Shoushtari et al., 2016); BRAF WT melanoma (NCT01941927) (Algazi 
et al., 2015); Cervical cancer (NCT01958112) 
Solid tumours (NCT01902173) 
GSK690693 
Monotherapy Phase I: Solid tumours (NCT00493818) 
IPATASERTIB (GDC-0068) 
Monotherapy 
Phase I: 
Phase II:  
Solid tumours (NCT01090960); Healthy subjects (NCT02536391, NCT02063581, NCT02390492) 
GBM (NCT02430363) 
Chemotherapy 
Paclitaxel 
mFOLFOX6 
Docetaxel 
TNBC (NCT02301988, NCT02162719); solid tumours (NCT01362374) (Isakoff et al., 2014) 
Gastro-oesophageal cancer (NCT01896531); solid tumours (NCT01362374) 
Solid tumours (NCT01362374) 
MAPK Cobimetinib Any cancer (NCT01562275) (Bendell et al., 2014) 
Hormonal 
Abiraterone + Pred 
Enzalutamide 
CRPC (NCT01485861) (De Bono et al., 2016) 
Solid tumours (NCT01362374) 
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LY2780301 
Monotherapy Phase I: Single agent  (NCT01115751) (Azaro et al., 2015) 
Combinations Paclitaxel 
Gemcitabine 
Breast cancer (NCT01980277) 
Solid tumours (NCT02018874) 
TRICIRIBINE (TCN-PM; VD-0002) 
Monotherapy Phase I: Solid tumours (NCT00363454) (Garrett et al., 2011a);Haematological malignancies(NCT00642031) 
Combinations Carboplatin Ovarian cancer (NCT01690468) 
MK2206 
Monotherapy 
Phase I: Solid tumours (NCT00670488, NCT01071018) (Doi et al., 2015; Yap et al., 2011, 2014); Paediatric tumours 
(NCT01231919) (Fouladi et al., 2014) 
Phase II: Solid tumours: Adenoid cystic carcinoma (NCT01604772) (Ho et al., 2015); Breast cancer (NCT01277757); Early breast 
cancer (NCT01319539); Biliary cancer (NCT01425879) (Ahn et al., 2015); Colorectal (NCT01802320) (Dasari et al., 2016); KRAS 
WT PIK3CA mutant CRC (NCT01186705); Endometrial cancer (NCT01312753, NCT01307631) (Konstantinopoulos et al., 2014); 
Gastro-oesophageal (NCT01260701) (Ramanathan et al., 2015); Head and neck cancer (NCT01349933) (Ma et al., 2015); Liver 
cancer (NCT01239355); Nasopharyngeal carcinoma (NCT01370070); Neuroendocrine tumours (NCT01169649); Ovarian/primary 
peritoneal/fallopian tube cancers with PI3K/AKT mutations or PTEN loss (NCT01283035) 
Haematological malignancies: AML (NCT01253447) (Konopleva et al., 2014); Lymphoma (NCT01258998) (Oki et al., 2015); 
Diffuse large B-cell lymphoma (NCT01466868, NCT01481129) 
Chemotherapy 
Paclitaxel 
Paclitaxel + Trastuzumab 
Carbo-taxol or Docetaxel 
Solid tumours + breast cancer (NCT01263145) (Gonzalez-Angulo et al., 2015) 
HER2+ve tumours (NCT01235897) (Chien et al., 2016) 
Solid tumours (NCT00848718) (Molife et al., 2014) 
HER2-directed 
Lapatinib 
Trastuzumab +/- Lapatinib 
 
HER2+ve breast cancer (NCT01281163, NCT01245205) (Wisinski et al., 2016) 
HER2+ve breast cancer (NCT01042379); HER2+ve solid tumours (NCT00963547, 
NCT01705340)(Hudis et al., 2013; Tripathy et al., 2015) 
MAPK 
Selumetinib 
 
Selumetinib + mFOLFOX 
Solid tumours (NCT01021748) (Tolcher et al., 2015a); Colorectal (NCT01333475) (Do et al., 2015); 
Melanoma (NCT01519427); NSCLC (NCT01248247) (Papadimitrakopoulou et al., 2014) 
ancreatic cancer (NCT01658943) (Chung et al., 2015) 
PI3K/mTOR 
Gefitinib 
Erlotinib 
 
Dalotuzumab 
Everolimus 
Ridaforolimus (MK8669) 
NSCLC (NCT01147211) (Lin et al., 2014) 
NSCLC (NCT01248247) (Papadimitrakopoulou et al., 2014); Erlotinib resistant NSCLC 
(NCT01294306) (Lara et al., 2015); Solid tumours (NCT00848718) (Molife et al., 2014) 
Any cancer (NCT01243762) (Brana et al., 2014) 
Renal cancer (NCT01239342)  
Any cancer (NCT01295632) (Gupta et al., 2015) 
Hormonal 
Anastrozole +/or 
Fulvestrant 
Anastrozole +/- Goserelin 
Bicalutamide 
ER +ve breast cancer (NCT01344031) (Ma et al., 2016) 
 
ER +ve HER2-ve breast cancer (NCT01776008)  
Prostate cancer (NCT01251861) 
Other 
Dinaciclib 
Bendamustine 
Hydrochloride, and 
Rituximab 
Hydroxychloroquine 
Pancreatic carcinoma (NCT01783171)  
CLL or small lymphocytic leukaemia (NCT01369849) 
 
 
Solid tumours (NCT01480154) 
PERIFOSINE 
Monotherapy 
Phase I: All solid tumours (Crul et al., 2002; Figg et al., 2014; Van Ummersen et al., 2004; Unger et al., 2010) (NCT00019656, 
NCT00062387, NCT00005794; NCT00005794);  
Phase II: Breast cancer (Leighl et al., 2008)(NCT00054145); NSCLC (NCT00399789); Malignant glioma (NCT00590954);  
Head and neck (Argiris et al., 2006)(NCT00062387); Melanoma (Ernst et al., 2005) (NCT00053781); Pancreatic cancer (Marsh et al., 
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2007) (NCT00059982, NCT00053924); Castrate resistant prostate cancer (Posadas et al., 2005)(NCT00060437); Biochemically 
recurrent prostate cancer (Chee et al., 2007) (NCT00058214); Renal carcinoma (Cho et al., 2012) (NCT00448721, NCT00498966); 
Soft tissue sarcoma (Bailey et al., 2006; Knowling et al., 2006) (NCT00053794, NCT00064324); Chemo resistant sarcoma 
(NCT00401388); Waldenstrom's macroglobulinemia (NCT00422656, NCT00398710); Leukaemia (NCT00391560). 
Chemotherapy/ 
Radiotherapy 
Docetaxel 
Radiotherapy 
Capecitabine 
Epithelial ovarian cancer (Fu et al., 2012)(NCT00431054) 
Solid tumours (Vink et al., 2006) 
Colorectal cancer (Bendell et al., 2011, 2012; Eng et al., 2014) (NCT01097018; NCT00398879) 
Targeted therapy 
Temsirolimus 
Imatinib 
Bortezomib +Dex 
Lenalidomide +Dex 
Sorafenib 
UCN-01 
Paediatric solid tumours (NCT01049841);Malignant Gliomas (NCT01051557,NCT02238496) 
GIST (NCT00455559) 
Multiple myeloma (Richardson et al., 2011)(NCT00401011, NCT01002248) 
Multiple myeloma (Jakubowiak et al., 2012) (NCT00415064) 
Lymphoprolierative diseases (Guidetti et al., 2014) 
Acute leukaemia, CML, high risk MDS (Gojo et al., 2013)(NCT00301938) 
 
Table 2: Table showing trials of AKT inhibitors in clinical development. 
Trials that are currently recruiting or remain open are marked in red. Allosteric 
inhibitors are shaded blue. Competitive ATP inhibitors are shaded purple. Dex = 
dexamethasone. CRPC (castrate resistant prostate cancer). TNBC (triple negative 
breast cancer). 
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Figure 1: Structural domains of AKT. 
Figure 2: Activation and negative regulation of AKT. See text for details. 
Figure 3: Diagram illustrating feedback inhibition and activation within AKT 
signalling. 
Figure 4: (A) Frequency of AKT1-3 amplification across a range of tumour types.. 
(B) AKT mutations are found in approximately 1% of all cancers. The frequency 
of AKT mutations vary between cancer types as shown. Data gathered from 
cbioportal.org database (Cerami et al. 2012; Gao et al. 2013). Only studies with 
n>100 included in analysis. 
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Figure 4A-B 
